Mesothelin expression in the leptomeninges and meningiomas

Journal of Histochemistry and Cytochemistry

Volumn 56, Issue 6, 2008, Pages 579-585

  Johnson, Mahlon D ^a   Vito, Fran ^a   O'Connell, Mary J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Arachnoid; Leptomeninges; Meningioma; Mesothelin

Indexed keywords

MESOTHELIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEPTOMENINX; MALE; MENINGIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARACHNOID; CHILD; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED;

EID: 43949099965     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/jhc.2008.950477     Document Type: Article

References (25)

1. Bera TK, Pastan I (2000) Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 20:2902-2906
2. Buccoliero AM, Castiglione F, Degl'Innocenti DR, Gheri CF, Garbini F, Taddei A, Ammannati F, et al. (2007) NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-PCR study. Neuropathology 27:36-42
3. Chang K, Pastan I (1992) Frequent expression of tumor antigen CAK1 in squamous-cell carcinomas. Int J Cancer 51:548-554
4. Chang K, Pastan I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers. Proc Natl Acad Sci USA 93:136-140
5. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, et al. (2007) Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 62: 569-576
6. Frierson HF, Moskaluk CA, Powell SM, Zhang H, Cerielli LA, Stoler MH, Cathro H, et al. (2003) Large-scale molecular and tissue array analysis of mesothelin in common human cancers. Hum Pathol 34:605-609
7. Gubbels JA, Belisle J, Onda M, Migneault CM, Ho M, Bera TK, Connor J, et al. (2006) Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 5:50-65
8. Hassan R, Bera T, Pastan I (2004) Mesothelin: a new target for immunotherapy. Clin Cancer Res 10:3937-3942
9. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, et al. (2006) Detection and quantification of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12:447-453
10. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I (2007) Mesothelin expression in human lung cancer. Clin Cancer Res 13:1571-1575
11. Hucl T, Brody JR, Gallmeier E, Iacobuzio-Donahue CA, Farrance IK, Kern SE (2007) High cancer-specific expression of mesothelin (MSLN) is attributable to upstream enhancer containing a tran-scription enhancer factor-dependent MCAT motif. Cancer Res 67:9055-9065
12. Jhala N, Jhala D, Vickers SM, Eltoum I, Batra SK, Manne U, Eloubeidi M, et al. (2006) Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. A translational research application. Am J Clin Pathol 126:572-579
13. Kojima T, Oh-eda M, Hattori K, Taniguchi Y, Tamura M, Ochi N, Yamaguchi N (1995) Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 270:21984-21990
14. Muminova ZE, Strong TV, Shaw DR (2004) Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer 4:19
15. Mutsaers SE (2002) Mesothelial cells: their structure, function and role in serosal repair. Respirology 7:171-191
16. Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH, Pastan I (2006) Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 12:4225-4231
17. Onda M, Willingham M, Nagata S, Bera TK, Beers R, Ho M, Hassan R, et al. (2005) New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, western blotting and ELISA. Clin Cancer Res 11:5840-5846
18. Ordonez NG (2003) Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 27:1418-1428
19. Perry A, Louis DN, Scheithauer BW, Budka H, von Deimling A (2007) Meningiomas. In Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. Tumours of the Nervous System. Geneva, WHO Press, 164-172
20. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A (2004) Binding of ovarian cancer cell antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279:9190-9198
21. Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, et al. (2006) Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173:1155-1160
22. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, Hellstrom I (1999) Soluble members of the mesothelin/megakaryocyte potentiating factor family are dectable in the sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 96: 11531-11536
23. Wellenreuther R, Waha A, Vogel Y, Lenartz D, Schramm J, Weistler OD, von Deimling A (1997) Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants. Lab Invest 77:601-606
24. Weller RO (2005) Microscopic morphology and histology of the human meninges. Morphologie 89:22-34
25. Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N (1994) A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem 269:805-808